News | September 04, 2014

Frost & Sullivan Recognizes Volpara for Identifying Importance of Dose Tracking and Quantitative Analytics in Early Breast Cancer Detection

Frost & Sullivan Recognizes Volpara for Identifying Importance of Dose Tracking and Quantitative Analytics in Early Breast Cancer Detection

September 4, 2014 — Based on its recent analysis of the breast imaging solutions market, Frost & Sullivan recognized Volpara Solutions with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership.

Over the past few years, Volpara has steadily introduced several new solutions and expanded its global reach to cover the United States, Europe, Asia and Australia. Volpara’s suite of quantitative solutions includes VolparaDose, VolparaDensity, VolparaAnalytics and VolparaResearch. The Density and Dose solutions are patient-specific, while the Analytics and Research solutions are clinic-wide monitoring tools.

“Frost & Sullivan lauds Volpara Solutions for continuous leadership in technology innovation, thoughtfulness in identifying the unmet need for dose tracking in breast imaging and a clear vision for what analytics can achieve in the early detection and treatment of breast cancer,” said Siddharth Sadha, research director, Advanced Medical Technologies Group, Frost & Sullivan.

“Furthermore, all of the applications are built to serve across both full-field digital mammography (FFDM) and digital tomosynthesis systems, and with multi-vendor compatibility and reproducible data. This is of high relevance in the industry, as tomosynthesis is quickly gaining currency, with 30 percent of the members of the Society of Breast Imaging in the U.S. already using it,” he said.

While several market participants offer breast density measurement tools, Frost & Sullivan confirmed Volpara Solutions is the only company with a dose measurement tool specifically for breast imaging. It is necessary to measure volumetric breast density to control the dose, and Volpara Solutions emerged as a pioneer in leveraging the mega-trend of dose reduction by acknowledging patient-specific dose tracking and reporting as a white-space opportunity.

“We are very proud to be recognized for the innovative solutions we have brought to the breast imaging market and for our vision and commitment to address unmet needs in the detection, prevention and treatment of breast cancer,” said Ralph Highnam, Ph.D., Volpara Solutions CEO and chief scientist. “By allowing researchers across the globe to compare data to detect geographical, racial and age-related trends, we hope to take breast cancer research to the next level, which could lead to the development of predictive analytical models that will revolutionize early detection of breast cancer and save lives.”

For more information: www.frost.com

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Densitas Enters Platform Partnership With Blackford
News | Breast Density | December 19, 2018
Breast imaging analytics company Densitas Inc. announced the signing of a new Alliance Partner Agreement with Blackford...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...